Steven Grant, M.D.

Affiliations: 
Virginia Commonwealth University, Richmond, VA, United States 
Area:
Pharmacology, Biochemistry
Website:
https://medschool.vcu.edu/expertise/detail.html?ID=845
Google:
"Steven Grant"
Mean distance: (not calculated yet)
 

Parents

Sign in to add mentor
Edwin C. Cadman post-doc 1978-1980 Yale School of Medicine (Cell Biology Tree)

Children

Sign in to add trainee
Roy H. Decker grad student 2001 VCU
Shujie Wang grad student 2002 VCU
Wesam B. Ahmed grad student 2003 VCU
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Nguyen T, Parker R, Hawkins E, et al. (2019) Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur and and proceed through multiple mechanisms. Oncotarget. 10: 5383-5384
Booth L, Roberts JL, Cruickshanks N, et al. (2019) Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs. Molecular Cancer Therapeutics. 18: 1669
Zhang Y, Zhou L, Bandyopadhyay D, et al. (2019) The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Dasmahapatra G, Lembersky D, Son MP, et al. (2019) Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells and . Molecular Cancer Therapeutics. 18: 1180
Dasmahapatra G, Lembersky D, Son MP, et al. (2019) Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells and . Molecular Cancer Therapeutics. 18: 1179
Han L, Zhang Q, Dail M, et al. (2019) Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica
Dasmahapatra G, Nguyen TK, Dent P, et al. (2019) Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]. Leukemia Research
Zhou L, Zhang Y, Leng Y, et al. (2019) The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. Journal of Hematology & Oncology. 12: 25
Nguyen T, Parker R, Zhang Y, et al. (2018) Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Bmc Cancer. 18: 1129
Yazbeck V, Shafer D, Perkins EB, et al. (2018) A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 18: 569-575.e1
See more...